Warning letterFDA · May 7, 2020
Chronic Lyme Treatments MARCS-CMS 607094, May 07, 2020
Named company: Chronic Lyme Treatments
Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are…
Lot information: not specified in this record.